|
printer friendly version
A validation study of Des-gamma carboxy-prothrombin for the detection of early hepatocellular carcinoma
Aim: To develop better biomarkers for the early detection of hepatocellular carcinoma (HCC).
Please notify of HCC cases: Sherry Fu at (734) 647-3635 (e-mail: sherryfu@umich.edu ) or Dr. Jorge A. Marrero jmarrero@umich.edu.
Prospective evaluation of tumor markers for the early
detection of hepatocellular carcinoma (HCC)
This is an extension of the above study. We plan
to follow a cohort of patients with cirrhosis over
time to identify the rate of development of HCC, to
validate novel biomarkers, and to stratify cirrhotic
patients into high- and low-risk for development of
HCC based on their exposures to tobacco, alcohol,
obesity, and other factors.
Specific Aims
- To determine if serum DCP, GP73, or a combination
of these markers is more sensitive than AFP for
the detection of early HCC.
- To determine if studies on proteomics of HCC can lead to the development of novel serum markers of early HCC.
- To determine if tobacco, alcohol, obesity, demographics,
and etiology of liver disease are important factors
for the development of HCC in patients with cirrhosis.
Please notify of patients with Child's A or B cirrhosis
who will be followed long-term: Sherry Fu at (734)
647-3635 (e-mail: sherryfu@umich.edu)
or Dr. Jorge A. Marrero at jmarrero@umich.edu
Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma
Patients with chronic liver disease are at risk of developing Hepatocellular Carcinoma (HCC). This research study will evaluate the potential outcome of patients with liver tumors. This study plans to evaluate the Barcelona staging system in patients with HCC and evaluate if new biomarker at the time of HCC diagnosis improves the accuracy of the Barcelona staging system in predicting the outcome of patients with liver cancer.
Specific Aims
- Evaluation of the prognosis of patients with Hepatocellular Carcinoma
- To prospectively evaluate the Barcelona staging system in patients with HCC
- To determine if novel biomarker expression at the time of HCC diagnosis improves the accuracy of the Barcelona staging system in predicting the prognosis of patients with HCC.
Please notify of HCC cases: Sherry Fu (734) 647-3635 or sherryfu@umich.edu or Dr. Jorge A. Marrero at jmarrero@umich.edu |
